Different expression patterns of MMP-2 and MMP-9 in breast cancer.

Among the many biological characteristics of cancer, the matrix metalloproteinase (MMPs) is essential for tumor invasion and metastasis. The relationship between MMP-2 and MMP-9 according to tumor progression has not been studied yet. We evaluated the synchronous expression and activation rate of MMP-2 and MMP-9 in breast cancer tissues and compared them to the clinical parameters in order to determine the clinical significance of MMPs and the possibilities of using them as a therapeutic target. The activity of MMPs was evaluated in 121 breast cancer tissues using zymography and the area of activation was calculated by computer-assisted densitometry in comparison to the activity of a positive control (HT-1080). In 121 tumor tissues, 32 (26.4%) did not express any form of MMPs and 19 (15.7%) showed both expression of MMP-2 and MMP-9. We observed that only one tissue expressed MMP-9 alone, while MMP-2 alone was expressed in 69 tissues. In 88 patients with MMP-2 and/or MMP-9 expression, we were unable to observe any correlation between the activity of MMPs expression or activation rate and the clinical parameters. But MMP-2 and MMP-9 activity increased according to T factor. Rapid production of MMP-9 occurred from T2 (p=0.046), while that of MMP-2 occurred from T3 (p=0.004). In conclusion, MMPs activity was organ specific. The major MMPs in breast cancer was MMP-2 and MMPs activity was different with tumor progression. When MMPs are a specific therapeutic target, we should use different inhibitors according to tumor size, in patients at the same stage.